RGEN Repligen Corporation

Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference

Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 39th Annual J.P. Morgan Healthcare conference being held January 11-14.  Tony J. Hunt, President and Chief Executive Officer, will make a formal presentation on Wednesday, January 13, at 9:10 a.m. EST.

A live webcast of the presentation will be accessible through the  section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881



EN
04/01/2021

Underlying

RGENRepligen Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Reports Third Quarter 2025 Financial Results and Updates Full...

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased sequentially and greater than 20% year-over-yearIncreasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, ...

October 28, 2025 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen to Report Third Quarter 2025 Financial Results

Repligen to Report Third Quarter 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2025. The conference ca...

October 15, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.42
INCY INCYTE CORP
TECH Bio-Techne Corp... ... (+26)

Vermilion Compass: Weekly Equity Strategy

Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...

INCY INCYTE CORP
TECH BIO-TECHNE CORPORATION
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
ENS ENERSYS
BIIB BIOGEN INC.
BGNE BEIGENE LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALNY ALNYLAM PHARMACEUTICALS INC
IONS IONIS PHARMACEUTICALS INC.
UTHR UNITED THERAPEUTICS CORPORATION
MDGL MADRIGAL PHARMACEUTICALS
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
AMPX AMPRIUS TECHNOLOGIES INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
TE ALUSSA ENERGY ACQUISITION CORP
10/08/25 October 8, 2025 1 EN
Free Trial
RGEN Repligen Corpor...

Repligen Corp: 1 director

A director at Repligen Corp sold after exercising options/sold 29,111 shares at 120.518USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

RGEN REPLIGEN CORPORATION
09/12/25 September 12, 2025 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Corporation to Present at Upcoming September Conferences

Repligen Corporation to Present at Upcoming September Conferences WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences. The Wells Fargo Healthcare Conference, being held September 3 – 5 in Boston. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 8:00 a.m. ET on Thursday, September 4, 2025.The Deutsche Bank Healthcare Summit, being held September 10 – 1...

August 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch